NO2563385T3 - - Google Patents

Info

Publication number
NO2563385T3
NO2563385T3 NO11778000A NO11778000A NO2563385T3 NO 2563385 T3 NO2563385 T3 NO 2563385T3 NO 11778000 A NO11778000 A NO 11778000A NO 11778000 A NO11778000 A NO 11778000A NO 2563385 T3 NO2563385 T3 NO 2563385T3
Authority
NO
Norway
Application number
NO11778000A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2563385T3 publication Critical patent/NO2563385T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO11778000A 2010-04-28 2011-04-28 NO2563385T3 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
PCT/US2011/034282 WO2011139820A1 (en) 2010-04-28 2011-04-28 Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Publications (1)

Publication Number Publication Date
NO2563385T3 true NO2563385T3 (enExample) 2017-12-30

Family

ID=44903987

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11778000A NO2563385T3 (enExample) 2010-04-28 2011-04-28

Country Status (17)

Country Link
US (1) US8808697B2 (enExample)
EP (3) EP2563385B1 (enExample)
JP (5) JP5899206B2 (enExample)
KR (1) KR20130086126A (enExample)
CN (2) CN105381451B (enExample)
AU (1) AU2011248540B2 (enExample)
CA (1) CA2795823C (enExample)
DK (1) DK2563385T3 (enExample)
EA (2) EA036805B8 (enExample)
ES (2) ES2826445T3 (enExample)
IL (1) IL222739A0 (enExample)
NO (1) NO2563385T3 (enExample)
NZ (1) NZ603196A (enExample)
PL (2) PL3260128T3 (enExample)
PT (2) PT2563385T (enExample)
SG (1) SG184907A1 (enExample)
WO (1) WO2011139820A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
WO2017136492A1 (en) * 2016-02-02 2017-08-10 Oncoimmune, Inc. Use of cd24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
EP3592375A4 (en) 2017-03-07 2021-01-20 Oncoimmune, Inc. METHOD OF USING SOLUBLE CD24 FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
CN110650749A (zh) * 2017-05-15 2020-01-03 肿瘤免疫股份有限公司 使用可溶性cd24进行神经保护和髓鞘再生的方法
WO2018217659A1 (en) * 2017-05-22 2018-11-29 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
KR20250122537A (ko) * 2018-05-14 2025-08-13 온코씨4, 아이앤씨. 항-cd24 조성물 및 이의 용도
WO2019236474A1 (en) * 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
EP4017508A1 (en) * 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
US20250195673A1 (en) * 2020-11-30 2025-06-19 Fred Hutchinson Cancer Center Compositions and methods for selective depletion of target molecules
CN118076625A (zh) * 2021-09-28 2024-05-24 广州昂科免疫生物技术有限公司 包含071核心肽的融合蛋白及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
PL367329A1 (en) * 2001-07-13 2005-02-21 Merck Patent Gmbh Methods for reducing immunogenicity of polypeptides
EP2292259A3 (en) * 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
HRP20090325T1 (en) * 2003-04-09 2009-07-31 Genentech Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
AU2004294547A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic CD24 genotypes that are predictive of multiple sclerosis risk and progression
WO2005113599A1 (en) * 2004-05-21 2005-12-01 Xencor, Inc. C1q family member proteins with altered immunogenicity
US20060160220A1 (en) * 2004-11-12 2006-07-20 Iogenetics Retroviral vectors with introns

Also Published As

Publication number Publication date
CN102869369A (zh) 2013-01-09
JP2017057216A (ja) 2017-03-23
EP3260128A1 (en) 2017-12-27
JP5899206B2 (ja) 2016-04-06
HK1176007A1 (zh) 2013-07-19
EA027735B1 (ru) 2017-08-31
CN105381451A (zh) 2016-03-09
SG184907A1 (en) 2012-11-29
ES2645262T3 (es) 2017-12-04
EA201790538A2 (ru) 2017-07-31
KR20130086126A (ko) 2013-07-31
CA2795823A1 (en) 2011-11-10
PT2563385T (pt) 2017-11-10
AU2011248540B2 (en) 2014-11-20
EP3845238A1 (en) 2021-07-07
JP2019151655A (ja) 2019-09-12
IL222739A0 (en) 2012-12-31
EP3260128B1 (en) 2020-07-29
CA2795823C (en) 2019-06-04
JP6062502B2 (ja) 2017-01-18
JP2013527168A (ja) 2013-06-27
EP2563385A4 (en) 2013-10-02
JP6526872B2 (ja) 2019-06-05
HK1222554A1 (zh) 2017-07-07
WO2011139820A8 (en) 2013-02-07
JP2018127493A (ja) 2018-08-16
EA036805B8 (ru) 2021-02-25
CN102869369B (zh) 2016-05-18
EA036805B1 (ru) 2020-12-23
PT3260128T (pt) 2020-10-22
WO2011139820A1 (en) 2011-11-10
EA201290961A1 (ru) 2013-04-30
ES2826445T3 (es) 2021-05-18
DK2563385T3 (da) 2017-11-06
EA201790538A3 (ru) 2017-11-30
JP6888221B2 (ja) 2021-06-16
PL3260128T3 (pl) 2021-02-08
CN105381451B (zh) 2021-03-09
EP2563385A1 (en) 2013-03-06
NZ603196A (en) 2014-07-25
JP2015187162A (ja) 2015-10-29
US8808697B2 (en) 2014-08-19
EP2563385B1 (en) 2017-08-02
PL2563385T3 (pl) 2018-04-30
US20130136739A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
BR112013008959A2 (enExample)
BR112012030039A2 (enExample)
BR112012019354A2 (enExample)
BR112012028408A2 (enExample)
BR112012029986A2 (enExample)
BR112012027808A2 (enExample)
BR112012024897A2 (enExample)
BR112012026492A2 (enExample)
BR112012031500A2 (enExample)
BR112012025307A2 (enExample)
BR112012017960A2 (enExample)
BR112012002126A2 (enExample)
BR112012026946A2 (enExample)
BR112012025482A2 (enExample)
BR112013006400A2 (enExample)
BR112012031826A2 (enExample)
BR112012023249A2 (enExample)
BR112012028186A2 (enExample)
BR112012025577A2 (enExample)
BR112012016456A2 (enExample)
BR112012018256A2 (enExample)
BR112012027015A2 (enExample)
BR112012025308A2 (enExample)
BR112012027945A2 (enExample)
BR112013010949A2 (enExample)